The book brings together the most up-to-date knowledge and expertise covering the whole topic of alcohol. It presents the practical skills needed to offer ethical intervention and treatment and implement ethical person-centered care. It is a practice-based text that aims to improve ethical relationships, responses, care and practice necessary to be effective in interventions and treatment with those experiencing alcohol use and health problems. The focus is on combining the principles and philosophy of alcohol prevention and intervention, in hospital and community. Each chapter provides self-assessment exercises, reflective practice exercises, key points and a "to learn more" section, and develops a theoretical framework, before broadening to include application in care and practice. This work will appeal to a wide readership, from professionals working within the mental health care and practice environment to mental health students.

Alcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the United States more than $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the United States with a 12-month diagnosis of AUD receive any treatment. Nevertheless, effective and evidence-based interventions are available, and treatment is associated with reductions in the risk of relapse and AUD-associated mortality. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individuals. The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD. In addition to reviewing the available evidence on the use of AUD pharmacotherapy, the guideline offers clear, concise, and actionable recommendation statements, each of which is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. The guideline provides guidance on implementing these recommendations into clinical practice, with the goal of improving quality of care and treatment outcomes of AUD.

This clinical guideline, commissioned by the National Institute for Health and Clinical Excellence (NICE) sets out clear recommendations, based on the best available evidence, for health care professionals on how to work with people with alcohol use disorders, in order to improve their treatment and care. About a quarter of the UK population drink alcohol at a level that is harmful and over 4% are dependent. Alcohol use disorders are also increasing in children and young people. This new guideline reviews the evidence for the diagnosis and assessment of alcohol use disorders, organisation and delivery of care, assisted alcohol withdrawal, and psychological and pharmacological interventions, and includes a chapter on experience of care. It comes with a free CD-ROM that contains all the data used as evidence, including: included and excluded studies, profile tables that summarise both the quality of the evidence and the results of the evidence synthesis, all meta-analytical data, presented as forest plots and detailed information about how to use and interpret forest plots.

This manual attempts to provide simple, adequate and evidence-based information to health care professionals in primary health care especially in low- and middle-income countries to be able to provide pharmacological treatment to persons with mental disorders. The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalized anxiety and sleep disorders; obsessive compulsive disorders and panic attacks; and alcohol and opioid dependence. The annexes provide information on evidence retrieval, assessment and synthesis and the peer view process.

The Australian Guidelines for the Treatment of Alcohol Problems have been periodically developed over the past 25 years. In 1993, the first version of these guidelines, titled: ‘An outline for the management of alcohol problems: Quality assurance in the treatment of drug dependence project’ was published (Mattick & Jarvis 1993). The Australian Government commissioned an update a decade later (Shand et al. 2003) and a further edition in 2009 to integrate the Guidelines with the Australian Guidelines to Reduce Health Risks from Drinking Alcohol (National Health and Medical Research Council, NHMRC 2009; Haber et al., 2009). The present version of the Guidelines was also commissioned by the Commonwealth of Australia to remain current and integrated with the updated NHMRC consumption guidelines (2020). In order to ensure that guidelines remain relevant, the next set of guidelines should be updated in 2025, consistent with NHMRC recommendation that guidelines be updated every five years. These guidelines aim to provide up-to-date, evidence-based information to clinicians on available treatments for people with alcohol problems and are largely directed towards individual clinicians in practice, such as primary care physicians (general practitioners, nursing staff), specialist medical practitioners, psychologists and other counsellors, and other health professionals. Some chapters highlight service or system level issues that impact on clinicians and their patients. These include recommendations concerning Aboriginal and Torres Strait Islander peoples, culturally and linguistically diverse groups, stigma, and discrimination. Elsewhere, organisation capacity is implied, such as medical resources for withdrawal management where recommendations indicate use of medications. As all forms of treatment will not be readily available or suitable for all populations or settings, these guidelines may require interpretation and adaptation.

For people with alcohol excess and liver disease, successful management must be two-fold with management of both their psychological/physical addiction to alcohol and their liver disease. Alcohol Abuse and liver disease, with its joint focus on hepatology and psychiatry, provides both hepatologists and psychiatrists of all levels with a practical, concise and didactic guide to the investigation and clinical management of those with alcohol-related problems. Edited by a practicing hepatologist in the UK and a practising specialist in psychiatry/substance abuse in the US, it covers areas such as: • Risk factors for alcoholic liver disease • Interaction of alcohol with other co-morbidities • Clinical assessment of alcohol intake • Detoxification and management of withdrawal • Psychotherapeutic and pharmaceutical interventions • Treatment of liver disease Key points, management diagrams and high-quality images are all be supported by the very latest in clinical guidelines from the major hepatology and psychiatry societies such as the APA, EPA, AASLD and EASL. With increasing emphasis on multi-disciplinary speciality care in this area, this is the ideal tool to consult in order to provide the best care possible care for what are very challenging patients to manage.